Introduction

30
Human noroviruses (NoVs) infections are considered a significant public health 31 problem, which cause more than 50% of non-bacterial gastroenteritis characterized by 32 fever, vomiting and diarrhea emerging frequently, espically in adults and children [1, 33 2]. NoVs divided into 5 genogroups designated GI through to GV and subdivided into 34 9 and 22 genotypes which was first linked to human disease in 1972 [3, 4] . From the 
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In the present study, we constructed GII.17 VP1 and expressed using 
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Construction of baculovirus expression vectors
74
The full-length capsid protein VP1 coding sequence (Genbank number, diluted at 1:1000 in PBS, added into 96-well plates (100 μL/well) and incubated at 4℃ 133 for overnight, followed by blocking with 5% milk diluted in PBS-T at 37℃ for 1h.
134
GII.17 VLP at 0.1 μg (100 μL)/well was incubated at 37℃ for 2 h, followed serum 135 samples that were diluted 1:1000 in PBS-T at 37℃ for 2 h with 100 μL /well. At last,
136
incubation with goat anti-mouse IgG HPR (Abcam, Ab6789, UK) at 37℃ for 1h.
137
Between each step, the plates were washed three times with PBS-T. The absorbance 138 was measured at 450 nm using a microplate reader. At the same time, we used PBS-T 139 without sera as a negative control.
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GII.17 VLPs-HBGAs binding blockade assay
141
The blocking activity of sera against GII.17 VLPs was determined by in vitro 
Results
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Expression and characterization of NoV GII.17 VLPs in sf9 cells 159 In order to confirm the expression of GII.17 VP1 protein in sf9 cells, EGFP and 160 VP1 genes were together cloned into pFastBac-Dual vector under the control of pH 161 and p10 promoters, respectively (Fig.1A) . The recombinant baculovirus was using (Fig.1B) . The purity and integrity of VLPs were showed by transmission 167 electron microscopy (Fig.1C) . It should be noted that smaller, larger and full VLPs been sweeping all over the world. Thus, it is highly desirable to formulate an effective 202 and rapid NoV GII.17 vaccine to achieve. In our study, we represented that the fist the results suggested that significant higher avidity for VLPs immunized mice and 208 also showed immunization route and adjuvants have no effect on the IgG avidity [28] .
209
Some of NoV VLPs candidates have shown efficacy in human trials [26, 29] . As we 210 known, the VP1 which can self-assemble into VLPs when expressed in sf9 cells using 211 recombinant baculovirus expression system [30] . Therefore, in our research, GII.17 Escherichia coli, expression of P domain can lead to formation of P-particle, a 12-or 225 24 dimers, which contained all the elements required for receptor binding 
